Guest guest Posted November 19, 2008 Report Share Posted November 19, 2008 Hi Everyone, For those of you who may not know, the IRIS trial was the phase II Gleevec trial that first compared Gleevec with Interferon. This was the landmark trial that resulted in Gleevec being front line therapy and is the trial that is being followed long term to track patients. This year we have the 7 year follow up data which can be found here: http://ash.confex.com/ash/2008/webprogram/Paper14057.html I'm pleased to report the following points: -progression free survival (those who have NOT progressed into accelerated or blast phase) after 7 years is 93% -those who remain in CCR after 7 years is 82% -only one patient who is in the trial has progressed to accelerated phase between years 6 and 7 which represents a mere 0.4% of patients. -The highest rate of progression happened in the second year of treatment (that was 2.8%). -the MMR rate (which they consider to be PCR's that are less than or equal to 0.1%)gets up to 85-90% between the 5th and 6th year. This is quite outstanding in my opinion and shows that the longer we're on Gleevec, the better results we get from it. Tracey Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.